Sugi Predict

Sugi Predict / Compounds / SCHEMBL2925046

SCHEMBL2925046

SCHEMBL2925046

O=C(O)c1c(SCc2ccccc2)ccc2nc(Nc3cccc(Cl)c3Cl)[nH]c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ EGLN1 Q9GZT9 2/20 0.37
▸ AR P10275 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ CTSB P07858 1/20 0.35
▸ TOP2A P11388 1/20 0.35
▸ PPARG P37231 2/20 0.35
▸ PBRM1 Q86U86 1/20 0.34
▸ METAP2 P50579 2/20 0.34
▸ P2RX7 Q99572 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ACMSD Q8TDX5 1/20 0.34
▸ MAPK1 P28482 1/20 0.33
▸ PTPRC P08575 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931417 0.91 MAPT (0.39) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL13176992 0.91 LMNA (0.38) MAPTLMNAEGLN1ARMRGPRX4
SCHEMBL2924883 0.85 MAPT (0.44) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL2927954 0.80 MAPT (0.39) MAPTKMT2AALDH1A1EGLN1PBRM1
SCHEMBL1115893 0.79 MAPT (0.42) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL13989934 0.76 MEN1 (0.45) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL2932570 0.76 MAPT (0.42) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL2931556 0.75 MAPT (0.39) MAPTMEN1KMT2AFABP3FABP4
SCHEMBL1116247 0.75 MAPT (0.44) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL12856603 0.74 MAPT (0.46) MAPTLMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910314-B1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2010-09-15 — — EP disclosed
EP-1910314-B1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2010-09-15 — — EP disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 — — US disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 — — US disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 — — US disclosed
EP-1910314-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES Novartis AG (CH) 2008-04-16 — — EP disclosed
WO-2007009774-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2007-01-25 — — WO disclosed
WO-2007009774-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2007-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306064-A1 Benzimidazole Derivatives PPARG, PPARD, BRD4 MAPT 2716/4885LMNA 1938/4885MEN1 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.